Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
Holding VRNA?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.05Last Year’s EPS
-$0.02Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: 19.10%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong positive sentiment primarily due to the successful launch of Ohtuvayre, robust prescriber engagement, and the initiation of new clinical trials. Despite the increased expenses and significant net loss, the overall outlook remains positive with promising early sales and a solid financial position.Company Guidance
In the third quarter of 2024, Verona Pharma achieved significant milestones, highlighted by the successful U.S. launch of Ohtuvayre for COPD treatment. In just 7 weeks, net sales reached $5.6 million, with more than 5,000 prescriptions filled and over 2,200 unique healthcare providers (HCPs) prescribing the drug. Around 30% of the targeted 2,500 Tier 1 HCPs have adopted Ohtuvayre, which is being prescribed across a diverse range of COPD patients, including those on single, dual, and triple therapies. The company has engaged over 90% of Tier 1 and Tier 2 HCPs, planning approximately 120 speaker programs by the year's end. Financially, Verona reported a net loss of $43 million for Q3, with $336 million in cash and equivalents, ensuring runway through 2026. The ongoing clinical development includes new Phase II trials, reflecting a robust strategy to expand Ohtuvayre's market presence.Successful Launch of Ohtuvayre
Ohtuvayre was launched for COPD treatment, achieving net product sales of $5.6 million in just 7 weeks, with October sales already exceeding Q3.
Strong Prescriber Engagement
More than 5,000 Ohtuvayre prescriptions filled and over 2,200 unique HCPs prescribing within 12 weeks of launch. About 90% of Tier 1 and Tier 2 HCPs reached through promotions.
Medicare Approval
Centers for Medicare and Medicaid Services approved a permanent product-specific J-Code for Ohtuvayre, effective January 2025.
Initiation of New Clinical Trials
Two new Phase II clinical programs were initiated, focusing on dose-ranging trials and nebulized ensifentrine for non-cystic fibrosis bronchiectasis.
Strong Financial Position
Verona maintains a strong balance sheet with $336 million in cash and equivalents, and potential access to $425 million under Oaktree facilities.
---
VRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $34.98 | $38.15 | +9.06% |
| Aug 08, 2024 | $19.53 | $21.60 | +10.60% |
| May 09, 2024 | $14.88 | $14.75 | -0.87% |
| Feb 29, 2024 | $17.26 | $17.22 | -0.23% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Verona Pharma Plc (VRNA) report earnings?
Verona Pharma Plc (VRNA) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Verona Pharma Plc (VRNA) earnings time?
Verona Pharma Plc (VRNA) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VRNA EPS forecast?
VRNA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.05.
---